News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (NASDAQ: ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and ...

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...

The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030" ...

Imagine if antibodies, hormones for fertility, proteins like insulin, and vaccines could be swallowed instead of taken by ...

The cocktail design of vaccine, tried on mice by Chinese scientists, mitigates the progression of fatty plaque in arteries ...

Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

It has been five years since the world was blown into the tumult of a lethal pandemic. Back then, deserted streets and ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $80 price target on Beam Therapeutics (BEAM) shares after the company ...

An international research project led by the University of Nebraska-Lincoln aims to transform the future of food by driving ...